Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259316 | 0.91 | TSHR (0.49) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL13165265 | 0.88 | TSHR (0.49) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL13641016 | 0.88 | TSHR (0.49) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL13640790 | 0.88 | TSHR (0.49) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL20151931 | 0.88 | ALDH1A1 (0.55) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12673953 | 0.88 | ALDH1A1 (0.55) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL11921661 | 0.88 | ALDH1A1 (0.55) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL18923938 | 0.85 | TSHR (0.56) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL18923980 | 0.85 | TSHR (0.56) | HPGDHTTSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL15257829 | 0.85 | GLP1R (0.45) | HPGDHTTSMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | HPGD 2879/4885HTT 167/4885SMN1; SMN2 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.